Bioresponsive nanocarriers for controlled and targeted delivery to efficiently treat Inflammatory Bowel Disease (IBD)

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1071796

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Despite considerable progress in treatment of Inflammatory Bowel Diseases, current treatments suffer from many disadvantages such as side effects, lack of efficacy in many patients, and development of drug dependence. Using state of art nanotechnology, novel nanoparticles will be developed to enhance the delivery to the intestine and efficacy of Budesonide (an anti-inflammatory steroid). This research promises to find safer and more effective ways to treat these diseases.

Funded Activity Details

Start Date: 01-01-2014

End Date: 01-01-2018

Funding Scheme: Early Career Fellowships

Funding Amount: $316,449.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Nanomedicine

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

drug delivery | formulation optimisation | inflammatory bowel disease (IBD) | nanotechnology | targeted therapy

Related Links